Laboratorios Richmond SACIF Class B

As of June 30, 2026, Laboratorios Richmond SACIF Class B carries a market capitalization of 128.39B, placing it among publicly traded companies globally. Its enterprise value stands at 369.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Laboratorios Richmond SACIF Class B has 80.75M shares outstanding.

As of June 30, 2026, Laboratorios Richmond SACIF Class B trades at a trailing price-to-earnings ratio of 10.52. The price-to-sales ratio is 0.98, and the price-to-book ratio stands at 1.09.

As of June 30, 2026, Laboratorios Richmond SACIF Class B trades at an EV/EBITDA multiple of 10.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.24 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Laboratorios Richmond SACIF Class B trades at an EV/FCF ratio of 126.90, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 369.19B versus a market cap of 128.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Laboratorios Richmond SACIF Class B maintains a current ratio of 0.92, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 204.61, indicating elevated leverage, while an interest coverage ratio of 1.84 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Laboratorios Richmond SACIF Class B posted a return on equity (ROE) of 12.65, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.18, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.26, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.24 indicates how many times Laboratorios Richmond SACIF Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Laboratorios Richmond SACIF Class B recorded 5.81B in income tax expense. That works out to an effective tax rate of 31.57, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 18.39B, leaving 12.21B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Laboratorios Richmond SACIF Class B's stock has gained approximately 18.70% over the past 52 weeks. The 50-day moving average sits at 1,517.90, while the 200-day moving average is 1,652.28.

Over the twelve months ended June 30, 2026, Laboratorios Richmond SACIF Class B generated 131.24B in revenue and converted that into 12.21B in net income, yielding earnings per share of 155.82. EBITDA reached 36.39B, while operating income came in at 24.21B.

As of June 30, 2026, Laboratorios Richmond SACIF Class B holds 3.87B in cash and equivalents against 243.51B in total debt, resulting in a net debt position of 218.98B. Total book value stands at 117.85B, with working capital of -8.23B providing operational flexibility.

Laboratorios Richmond SACIF Class B produced 10.61B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -21.24B in capital expenditures, free cash flow totaled -10.62B - equivalent to -131.56 per share.

Over the twelve months ended June 30, 2026, Laboratorios Richmond SACIF Class B posted a gross margin of 62.25, reflecting its pricing power and cost economics. The operating margin of 18.45 and net profit margin of 9.30 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Laboratorios Richmond SACIF Class B paid dividends of -7.78 per share. The dividend payout ratio of -5.06 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -8.27: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.29, meaning Laboratorios Richmond SACIF Class B raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Laboratorios Richmond SACIF Class B has an Altman Z-Score of 0.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.